IOTA Pharmaceuticals

Email Usinfo@iotapharma.com

Call Us+ 44 1223 421430

IOTA Pharmaceuticals

 
Fragment - based Drug Discovery
Neglected Parasitic Disease
Glioma & Glioblastoma
 
 
IOTA Pharmaceuticals

We have created IOTA specifically to serve researchers in the emerging area of fragment-based drug discovery. This field, covering as it does both structure-based drug design, high-content drug screening and structure-guided, property-based lead optimization, is one of the most important and exciting areas in drug discovery today.

IOTA is collaborating with The Drug Design Resource to provide researchers with regularly updated resources in the field of fragment-based drug discovery. Welcome to the world of fragment-based drug discovery!

 
FBDD OVERVIEW
FRAGMENT-BASED DRUG DESIGN: WHY IT'S SO IMPORTANT

Within the space of only a few years, fragment-based drug design (FBDD) has emerged as an efficient and productive route for de novo drug discovery. In this overview of the FBDD approach IOTA co-founders David Bailey, Susan Boyd, Paul England and Iwan de Esch, review FBDD and its role in design-led discovery biology.

FBDD LITERATURE
FRAGMENT-BASED DRUG DESIGN: THE LITERATURE

In partnership with the Drug Design Resource, IOTA is assembling a comprehensive FBDD literature review as a service to scientists working in the FBDD area. An updated version of this literature review can be found here.

If you have published a paper in the FBDD area which should be included in this list and does not currently appear, please send an email to david.bailey@iotapharma.com and we will include it.

FBDD MOLECULAR TARGETS
FRAGMENT-BASED DRUG DESIGN: MOLECULAR TARGETS

A growing number of proteins have been published as targets for FBDD studies. An updated list can be found here.

If you have published a paper in the FBDD area on a target which should be included in this list and does not currently appear, please send an email to david.bailey@iotapharma.com and we will include it.

FBDD CENTERS
FRAGMENT-BASED DRUG DESIGN: THE PLAYERS

A growing number of companies and academic centers are using and commercialising FBDD approaches. An updated list can be found here.

If you are a player in the FBDD area and wish to be included in this list, please send an email to david.bailey@iotapharma.com fragment binding modes. Through its partners, IOTA can screen hits from any of its own libraries, or your proprietary libraries, or your single compounds of interest, using soaking experiments with a range of crystal targets.

RSS